Literature DB >> 17483064

Unrelated-donor bone marrow transplantation with a conditioning regimen including fludarabine, busulfan, and 4 Gy total body irradiation.

Yasushi Onishi1, Shin-ichiro Mori, Shigeru Kusumoto, Kyoko Sugimoto, Daigo Akahane, Yuriko Morita-Hoshi, Sung-Won Kim, Takahiro Fukuda, Yuji Heike, Ryuji Tanosaki, Kensei Tobinai, Yoichi Takaue.   

Abstract

We investigated the feasibility of reduced-intensity conditioning with 4 Gy total body irradiation, fludarabine (30 mg/m2 for 6 days), and busulfan (4 mg/kg for 2 days) for bone marrow transplantation from a serologically HLA-matched unrelated donor. Seventeen adult patients (median age, 55 years; range, 27-67 years) with various hematologic malignancies (6 in remission, 11 not in remission) were treated. Successful engraftment was achieved in all patients at a median of day 18 (range, day 14-35) after transplantation, although subsequent secondary graft failure was observed in 2 patients. The cumulative incidence of acute graft-versus-host disease (GVHD) of grades II to IV at day 100 was 48%. With a median follow-up of 286 days (range, 56-687 days), the rates of 1-year overall survival, 100-day nonrelapse mortality, and 1-year nonrelapse mortality were 41%, 14%, and 46%, respectively. Eleven patients died, and the causes of death were relapse (n = 4), pulmonary complications (n = 4), acute GVHD (n = 2), and sepsis (n = 1). The remaining 6 patients (at transplantation, 2 were in remission, and 4 were not in remission) are currently still in remission. These results suggest that this regimen reduces the risk of graft failure, but further studies are needed to ameliorate transplantation-related toxicities, primarily GVHD and/or pulmonary complications.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17483064     DOI: 10.1532/IJH97.06199

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  27 in total

Review 1.  Chronic graft-versus-host disease and other late complications of bone marrow transplantation.

Authors:  K M Sullivan; E Agura; C Anasetti; F Appelbaum; C Badger; S Bearman; K Erickson; M Flowers; J Hansen; T Loughran
Journal:  Semin Hematol       Date:  1991-07       Impact factor: 3.851

2.  Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen.

Authors:  Ronjon Chakraverty; Karl Peggs; Rajesh Chopra; Donald W Milligan; Panagiotis D Kottaridis; Stephanie Verfuerth; Johanne Geary; Dharsha Thuraisundaram; Kate Branson; Suparno Chakrabarti; Premini Mahendra; Charles Craddock; Anne Parker; Ann Hunter; Geoff Hale; Herman Waldmann; Catherine D Williams; Kwee Yong; David C Linch; Anthony H Goldstone; Stephen Mackinnon
Journal:  Blood       Date:  2002-02-01       Impact factor: 22.113

3.  Outcomes of alemtuzumab-based reduced intensity conditioning stem cell transplantation using unrelated donors for myelodysplastic syndromes.

Authors:  Zi Yi Lim; Aloysius Y L Ho; Wendy Ingram; Michelle Kenyon; Laurence Pearce; Barbara Czepulkowski; Stephen Devereux; Rafael F Duarte; Antonio Pagliuca; Ghulam J Mufti
Journal:  Br J Haematol       Date:  2006-08-25       Impact factor: 6.998

4.  Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy.

Authors:  S Giralt; E Estey; M Albitar; K van Besien; G Rondón; P Anderlini; S O'Brien; I Khouri; J Gajewski; R Mehra; D Claxton; B Andersson; M Beran; D Przepiorka; C Koller; S Kornblau; M Kørbling; M Keating; H Kantarjian; R Champlin
Journal:  Blood       Date:  1997-06-15       Impact factor: 22.113

5.  Dose-reduced conditioning and allogeneic hematopoietic stem cell transplantation from unrelated donors in 42 patients.

Authors:  M Bornhäuser; C Thiede; U Platzbecker; A Jenke; A Helwig; R Plettig; J Freiberg-Richter; C Röllig; G Geissler; K Lutterbeck; U Oelschlagel; G Ehninger
Journal:  Clin Cancer Res       Date:  2001-08       Impact factor: 12.531

6.  CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells.

Authors:  G Hale; P Jacobs; L Wood; W E Fibbe; R Barge; N Novitzky; C Toit; L Abrahams; V Thomas; D Bunjes; C Duncker; M Wiesneth; D Selleslag; M Hidajat; M Starobinski; P Bird; H Waldmann
Journal:  Bone Marrow Transplant       Date:  2000-07       Impact factor: 5.483

7.  Allogeneic hematopoietic stem cell transplantation from family members other than HLA-identical siblings over the last decade (1991-2000).

Authors:  Yoshinobu Kanda; Shigeru Chiba; Hisamaru Hirai; Hisashi Sakamaki; Tohru Iseki; Yoshihisa Kodera; Takahiro Karasuno; Shinichiro Okamoto; Noriyuki Hirabayashi; Koji Iwato; Atsuo Maruta; Yoshihiro Fujimori; Tatsuo Furukawa; Shin Mineishi; Keitaro Matsuo; Nobuyuki Hamajima; Masahiro Imamura
Journal:  Blood       Date:  2003-04-24       Impact factor: 22.113

8.  Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years.

Authors:  Raymond Wong; Sergio A Giralt; Thomas Martin; Daniel R Couriel; Athanasios Anagnostopoulos; Chitra Hosing; Borje S Andersson; Pedro Cano; Munir Shahjahan; Cindy Ippoliti; Elihu H Estey; John McMannis; James L Gajewski; Richard E Champlin; Marcos de Lima
Journal:  Blood       Date:  2003-07-03       Impact factor: 22.113

9.  Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning.

Authors:  Aloysius Y L Ho; Antonio Pagliuca; Michelle Kenyon; Jane E Parker; Aleksandar Mijovic; Stephen Devereux; Ghulam J Mufti
Journal:  Blood       Date:  2004-04-01       Impact factor: 22.113

10.  Cyclosporine and mycophenolate mofetil prophylaxis with fludarabine and melphalan conditioning for unrelated donor transplantation: a prospective study of 22 patients with hematologic malignancies.

Authors:  R Rodriguez; P Parker; A Nademanee; D Smith; M R O'Donnell; A Stein; D S Snyder; H C Fung; A Y Krishnan; L Popplewell; S Cohen; G Somlo; M Angelopoulou; Z Al-Kadhimi; P M Falk; R Spielberger; N Kogut; F Sahebi; D Senitzer; M Slovak; J Schriber; S J Forman
Journal:  Bone Marrow Transplant       Date:  2004-06       Impact factor: 5.483

View more
  8 in total

1.  Favorable outcomes of intravenous busulfan, fludarabine, and 400 cGy total body irradiation-based reduced-intensity conditioning allogeneic stem cell transplantation for acute myelogenous leukemia with old age and/or co-morbidities.

Authors:  Sung-Eun Lee; Hee-Je Kim; Woo-Sung Min; Byung-Sik Cho; Ki-Seong Eom; Yoo-Jin Kim; Chang-Ki Min; Seok Lee; Seok-Goo Cho; Dong-Wook Kim; Jong-Wook Lee; Chong-Won Park; Chun-Choo Kim
Journal:  Int J Hematol       Date:  2010-08-10       Impact factor: 2.490

2.  Reduced-intensity conditioning by fludarabine/busulfan without additional irradiation or T-cell depletion leads to low non-relapse mortality in unrelated bone marrow transplantation.

Authors:  Takahiko Nakane; Hirohisa Nakamae; Hideo Koh; Mika Nakamae; Yoshiki Hayashi; Mitsutaka Nishimoto; Takuro Yoshimura; Eri Inoue; Atsushi Inoue; Ran Aimoto; Mizuki Aimoto; Yoshiki Terada; Ki-Ryang Koh; Takahisa Yamane; Masayuki Hino
Journal:  Int J Hematol       Date:  2011-03-12       Impact factor: 2.490

3.  Reduced-intensity conditioning regimen with low-dose ATG-F for unrelated bone marrow transplant is associated with lower non-relapse mortality than a regimen with low-dose TBI: a single-center retrospective analysis of 103 cases.

Authors:  Shigeo Fuji; Niina Ueno; Nobuhiro Hiramoto; Yoshitaka Asakura; Kimikazu Yakushijin; Yutaro Kamiyama; Saiko Kurosawa; Sung-Won Kim; Yuji Heike; Takuya Yamashita; Takahiro Fukuda
Journal:  Int J Hematol       Date:  2013-10-04       Impact factor: 2.490

4.  Mycophenolate mofetil combined with tacrolimus and minidose methotrexate after unrelated donor bone marrow transplantation with reduced-intensity conditioning.

Authors:  Chisaki Mizumoto; Junya Kanda; Tatsuo Ichinohe; Takayuki Ishikawa; Masashi Matsui; Norimitsu Kadowaki; Tadakazu Kondo; Kazunori Imada; Masakatsu Hishizawa; Hiroshi Kawabata; Momoko Nishikori; Kouhei Yamashita; Akifumi Takaori-Kondo; Toshiyuki Hori; Takashi Uchiyama
Journal:  Int J Hematol       Date:  2009-04-11       Impact factor: 2.490

5.  The Efficacy of an Oral Elemental Diet in Patients Undergoing Hematopoietic Stem Cell Transplantation.

Authors:  Takanobu Morishita; Natsuko Tsushita; Kanae Imai; Toshiyasu Sakai; Kotaro Miyao; Reona Sakemura; Tomonori Kato; Keiko Niimi; Yoshitaka Ono; Masashi Sawa
Journal:  Intern Med       Date:  2016-12-15       Impact factor: 1.271

6.  National survey on total-body irradiation prior to reduced-intensity stem cell transplantation in Japan: The Japanese Radiation Oncology Study Group.

Authors:  Hiroki Kawaguchi; Toshinori Soejima; Naoya Ishibashi; Takeshi Akiba; Masatoshi Hasegawa; Kouichi Isobe; Hitoshi Ito; Michiko Imai; Yasuo Ejima; Masaharu Hata; Keisuke Sasai; Emiko Shimoda; Masahiko Oguchi; Tetsuo Akimoto
Journal:  J Radiat Res       Date:  2019-10-23       Impact factor: 2.724

7.  Reduced-intensity stem cell transplantation for acute myeloid leukemia with fludarabine-based conditioning with intravenous busulfan versus melphalan.

Authors:  Takuya Yamashita; Akiyoshi Takami; Naoyuki Uchida; Takahiro Fukuda; Tetsuya Eto; Souichi Shiratori; Shuichi Ota; Takashi Akasaka; Shigesaburo Miyakoshi; Tadakazu Kondo; Michihiro Hidaka; Junya Kanda; Yoshiko Atsuta; Shingo Yano
Journal:  Bone Marrow Transplant       Date:  2020-03-12       Impact factor: 5.483

8.  TBI with lung dose reduction does not improve hematopoietic cell homing to BM during allogeneic transplantation.

Authors:  A K Singh; J Chen; R Calado; A Sowers; J B Mitchell; A J Barrett
Journal:  Bone Marrow Transplant       Date:  2009-06-15       Impact factor: 5.483

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.